摘要
目的探析甘精胰岛素联合瑞格列奈治疗2型糖尿病的疗效。方法将该院于2019年10月—2020年12月收治的96例2型糖尿病作为研究对象,以双盲法为基础将其分组,即观察组、对照组,对照组使用瑞格列奈治疗,观察组在对照组基础上联合甘精胰岛素治疗。比较两组患者的血糖水平、胰岛素消耗量、不良反应、总有效率以及血糖达标时间。结果观察组治疗有效率明显提升,差异有统计学意义(P<0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05);两组空腹血糖、餐后2 h血糖水平以及糖化蛋白水平比较,差异有统计学意义(P<0.05);观察组在治疗后胰岛素消耗量、血糖达标时间与对照组比较,差异有统计学意义(P<0.05)。结论2型糖尿病治疗中同时应用甘精胰岛素、瑞格列奈两种药物,获得较好效果。相对于常规的单一药物-瑞格列奈治疗,临床效果增强,且在短时间内改善患者的血糖水平,使其恢复正常指标。与此同时,还可降低胰岛素消耗量,值得临床上广泛推荐应用。
Objective To explore the efficacy of insulin glargine combined with repaglinide in the treatment of type 2 diabetes.Methods 96 cases of type 2 diabetes were treated in the hospital from October 2019 to December 2020 as the object of the research.They were divided into groups based on the double-blind method,namely observation group and control group.2.Control groups were treated with riglinel,the observation group was treated when combined with insulin saccharin on a control basis.Blood glucose levels,insulin consumption,adverse reactions,total efficiency,and blood glucose standard time were compared between the two groups.Results The effective rate of treatment in the observation group was significantly improved,the difference was statistically significant(P<0.05);the incidence of adverse reactions in the observation group compared with the control group,the difference was not statistically significant(P>0.05);compared the fasting blood glucose,two-hour postprandial blood glucose levels and glycosylated protein levels between the two groups,the difference was statistically significant(P<0.05);the observation group's insulin consumption and blood glucose reaching target time after treatment compared with the control group,the difference was statistically significant(P<0.05).Conclusion The simultaneous application of insulin glargine and repaglinide in the treatment of type 2 diabetes has achieved better results.Compared with the conventional single drug-repaglinide treatment,the clinical effect is enhanced,and the patient's blood glucose level can be improved in a short period of time to return to normal indicators.At the same time,it can also reduce insulin consumption,which is worthy of clinical recommendation and application.
作者
李小双
LI Xiaoshuang(Chinese Pharmacy,Shandong Guoxin Yiyang Group Zibo Hospital,Zibo,Shandong Province,255120 China)
出处
《糖尿病新世界》
2021年第17期89-92,共4页
Diabetes New World Magazine
